Preclinical data demonstrate enhanced systemic exposure and bioavailability, reduced dermal toxicit...
- Biogen gains rights to develop and commercialize subcutaneous (SC) formulations for two products ...
DAEJEON, South Korea, Jan. 20, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170) announced today ...
* EYLUXVI® is the second biosimilar approved for Alteogen following the launch of the Herceptin® ...
* CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package c...
DAEJEON, South Korea, Nov. 10, 2024 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced today t...
* Tergase® poised to capture a fair share of the global hyaluronidase market. DAEJEON, South Kore...
DAEJEON, South Korea, July 1, 2024 /PRNewswire/ -- Alteogen Inc.
Alteogen expects Tergase® will replace commercially available animal-derived hyaluronidase products...
* Altos Biologics, a subsidiary of Alteogen, is actively engaged in Eylea® Biosimilar (ALT-L9) cl...